| SAN DIEGO, Nov 13, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Gen-Probe Incorporated
(Nasdaq: GPRO) announced today that the Company will present at the Lazard
Capital Markets 5th Annual Healthcare Conference on Tuesday, November 18, 2008
at approximately 3:10 p.m. Eastern Time. The presentation is scheduled to be
webcast live and may be accessed through a link on the investors section of
Gen-Probe's website at http://www.gen-probe.com. The webcast will be available
for 30 days following the event.
About Gen-Probe
Gen-Probe Incorporated is a global leader in the development, manufacture
and marketing of rapid, accurate and cost-effective nucleic acid tests (NATs)
that are used primarily to diagnose human diseases and screen donated human
blood. Gen-Probe has approximately 25 years of NAT expertise, and received the
2004 National Medal of Technology, America's highest honor for technological
innovation, for developing NAT assays for blood screening. Gen-Probe is
headquartered in San Diego and employs approximately 1,000 people. For more
information, go to http://www.gen-probe.com.
Caution Regarding Forward-Looking Statements
Any statements in this press release about our expectations, beliefs,
plans, objectives, assumptions or future events or performance are not
historical facts and are forward-looking statements. Forward-looking
statements are not guarantees of performance. They involve known and unknown
risks, uncertainties and assumptions that may cause actual results, levels of
activity, performance or achievements to differ materially from those
expressed or implied. For information about risks and uncertainties we face
and a discussion of our financial statements and footnotes, see documents we
have filed with the SEC, including the Form 10-Q for the period ended
September 30, 2008, and all subsequent periodic filings made with the SEC. We
assume no obligation and expressly disclaim any duty to update any
forward-looking statement to reflect events or circumstances after the date of
this press release or to reflect the occurrence of unanticipated events.
Contact:
Paula Izidoro
Investor Relations
858-410-8904
SOURCE Gen-Probe Incorporated
http://www.gen-probe.com
|
